BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med 2017;37:19-24. [PMID: 27784575 DOI: 10.1016/j.ejim.2016.10.007] [Cited by in Crossref: 94] [Cited by in F6Publishing: 80] [Article Influence: 15.7] [Reference Citation Analysis]
Number Citing Articles
1 Paz MFCJ, de Alencar MVOB, de Lima RMP, Sobral ALP, do Nascimento GTM, Dos Reis CA, Coêlho MDPSS, do Nascimento MLLB, Gomes Júnior AL, Machado KDC, de Menezes APM, de Lima RMT, de Oliveira Filho JWG, Dias ACS, Dos Reis AC, da Mata AMOF, Machado SA, Sousa CDC, da Silva FCC, Islam MT, de Castro E Sousa JM, Melo Cavalcante AAC. Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer. Oxid Med Cell Longev 2020;2020:3457890. [PMID: 32308801 DOI: 10.1155/2020/3457890] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Arabyat RM, Nusair MB, Al-Azzam SI, Alzoubi KH. Analysis of prevalence, risk factors, and potential costs of unnecessary drug therapy in patients with chronic diseases at the outpatient setting. Expert Rev Pharmacoecon Outcomes Res 2020;20:125-32. [PMID: 31021675 DOI: 10.1080/14737167.2019.1612243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 24.7] [Reference Citation Analysis]
4 Savarino E, Marabotto E, Zentilin P, Furnari M, Bodini G, Pellegatta G, Lorenzon G, Della Coletta M, Ghisa M, Coppo C, Marinelli C, Savarino V. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety 2018;17:785-94. [DOI: 10.1080/14740338.2018.1497155] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
5 Vilcu AM, Sabatte L, Blanchon T, Souty C, Maravic M, Lemaitre M, Steichen O, Hanslik T. Association Between Acute Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses. JAMA Netw Open 2019;2:e1916205. [PMID: 31774521 DOI: 10.1001/jamanetworkopen.2019.16205] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
6 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
7 Alamoudi BM, Ibrahim NK, Kalo BBM. Are proton pump inhibitors among the risk factors for acute coronary syndrome? A multi-centric case-control study between patients attending governmental hospitals in western Saudi Arabia. Saudi Med J 2019;40:1098-104. [PMID: 31707405 DOI: 10.15537/smj.2019.11.24602] [Reference Citation Analysis]
8 Brito SA, de Almeida CLF, de Santana TI, da Silva Oliveira AR, do Nascimento Figueiredo JCB, Souza IT, de Almeida LL, da Silva MV, Borges AS, de Medeiros JW, da Costa Silva Neto J, de Cássia Ribeiro Gonçalves R, Kitagawa RR, Sant'Ana AEG, Rolim LA, de Menezes IRA, da Silva TG, Caldas GFR, Wanderley AG. Antiulcer Activity and Potential Mechanism of Action of the Leaves of Spondias mombin L. Oxid Med Cell Longev 2018;2018:1731459. [PMID: 29854075 DOI: 10.1155/2018/1731459] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
9 Horvath A, Stadlbauer V. [Proton Pump Inhibitors and their Microbiome-Mediated Side Effects]. Zentralbl Chir 2021;146:165-9. [PMID: 33327006 DOI: 10.1055/a-1312-7587] [Reference Citation Analysis]
10 Babic A, Zhang X, Morales-Oyarvide V, Yuan C, Khalaf N, Khalili H, Lochhead P, Chan AT, Ogino S, Wolpin BM, Wu K, Fuchs CS, Giovannucci EL, Stampfer MJ, Ng K. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer 2020;123:844-51. [PMID: 32541871 DOI: 10.1038/s41416-020-0939-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Kheloufi F, Frankel D, Kaspi E, Lepelley M, Mallaret M, Boucherie Q, Roll P, Micallef J. Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis. Therapies 2018;73:273-81. [DOI: 10.1016/j.therap.2017.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
12 Gamelas V, Salvado V, Dias L. Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol 2019;26:114-20. [PMID: 30976616 DOI: 10.1159/000488506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rettura F, Bronzini F, Campigotto M, Lambiase C, Pancetti A, Berti G, Marchi S, de Bortoli N, Zerbib F, Savarino E, Bellini M. Refractory Gastroesophageal Reflux Disease: A Management Update. Front Med (Lausanne) 2021;8:765061. [PMID: 34790683 DOI: 10.3389/fmed.2021.765061] [Reference Citation Analysis]
14 Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini A. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Eur J Cancer 2021;142:18-28. [PMID: 33212418 DOI: 10.1016/j.ejca.2020.09.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
15 Loosen SH, Kostev K, Luedde M, Qvartskhava N, Luedde T, Roderburg C. Long-term use of proton pump inhibitors (PPIs) is associated with an increased risk of type 2 diabetes. Gut 2021:gutjnl-2021-326297. [PMID: 34725199 DOI: 10.1136/gutjnl-2021-326297] [Reference Citation Analysis]
16 Marabotto E, Ziola S, Savarino V, Giannini EG, Furnari M, Bodini G, Zingone F, Ghisa M, Barberio B, Zentilin P, Savarino E. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. Clin Exp Gastroenterol 2020;13:99-104. [PMID: 32346304 DOI: 10.2147/CEG.S228352] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Lexne E, Brudin L, Strain JJ, Nylander PO, Marteinsdottir I. Temperament and character in patients with acute abdominal pain. Compr Psychiatry 2018;87:128-33. [PMID: 30367986 DOI: 10.1016/j.comppsych.2018.09.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Fuentes-Valenzuela E, Díez Redondo P, Tejedor-Tejada J, Nájera-Muñoz R, Sánchez-Delgado L, Maroto-Martín C. [Proton-pump inhibitors treatment. Does your patient really need it?]. Semergen 2021:S1138-3593(21)00266-5. [PMID: 34728148 DOI: 10.1016/j.semerg.2021.08.002] [Reference Citation Analysis]
19 Ma T, Wu M, Jia S, Yang L. Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies. Int J Colorectal Dis 2020;35:2157-69. [DOI: 10.1007/s00384-020-03717-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
20 Brozek W, Reichardt B, Zwerina J, Dimai HP, Klaushofer K, Zwettler E. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study. Osteoporos Int 2017;28:1587-95. [DOI: 10.1007/s00198-017-3910-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
21 Kherad O, Restellini S, Martel M, Barkun A. Proton pump inhibitors for upper gastrointestinal bleeding. Best Practice & Research Clinical Gastroenterology 2019;42-43:101609. [DOI: 10.1016/j.bpg.2019.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Martinucci I, Blandizzi C, Bodini G, Marabotto E, Savarino V, Marchi S, de Bortoli N, Savarino E. Vonoprazan fumarate for the management of acid-related diseases. Expert Opin Pharmacother 2017;18:1145-52. [PMID: 28657473 DOI: 10.1080/14656566.2017.1346087] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
23 Yang YSH, Chang HW, Lin IH, Chien LN, Wu MJ, Liu YR, Chu PG, Xie G, Dong F, Jia W, Chang VHS, Yen Y. Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats. Sci Rep 2020;10:866. [PMID: 31964941 DOI: 10.1038/s41598-020-57612-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
24 Lei Y, Liu X, Liu J, Zhang M, Zhou Y, Yan W, Tian D, Zhang P, Han P. Inverse Association Between Helicobacter pylori Infection and Unexplained Isolated Terminal Ileitis: A Retrospective Study. J Inflamm Res 2021;14:3015-21. [PMID: 34262325 DOI: 10.2147/JIR.S319561] [Reference Citation Analysis]
25 Costantino G, Furlan L, Bracco C, Cappellini MD, Casazza G, Nunziata V, Cogliati CB, Fracanzani A, Furlan R, Gambassi G, Manetti R, Manna R, Piccoli A, Pignone AM, Podda G, Salvatore T, Sella S, Squizzato A, Tresoldi M, Perticone F, Pietrangelo A, Corazza GR, Montano N. Impact of implementing a Choosing Wisely educational intervention into clinical practice: The CW-SIMI study (a multicenter-controlled study). Eur J Intern Med 2021:S0953-6205(21)00250-8. [PMID: 34353705 DOI: 10.1016/j.ejim.2021.07.008] [Reference Citation Analysis]
26 Huang WS, Bai YM, Hsu JW, Huang KL, Tsai CF, Su TP, Li CT, Lin WC, Tsai SJ, Pan TL, Chen TJ, Chen MH. Use of Proton Pump Inhibitors and Risk of Major Depressive Disorder: A Nationwide Population-Based Study. Psychother Psychosom 2018;87:62-4. [PMID: 29306949 DOI: 10.1159/000485190] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
27 Thong BKS, Ima-Nirwana S, Chin KY. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved. Int J Environ Res Public Health 2019;16:E1571. [PMID: 31060319 DOI: 10.3390/ijerph16091571] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
28 Scarpignato C, Tolone S. Addressing long-term PPI safety. Digestive and Liver Disease 2020;52:853-6. [DOI: 10.1016/j.dld.2020.05.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Del Giorno R, Ceschi A, Pironi M, Zasa A, Greco A, Gabutti L. Multifaceted intervention to curb in-hospital over-prescription of proton pump inhibitors: A longitudinal multicenter quasi-experimental before-and-after study. Eur J Intern Med 2018;50:52-9. [PMID: 29274884 DOI: 10.1016/j.ejim.2017.11.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
30 Mino-León D, Sánchez-García S, Giraldo-Rodríguez L, Reyes-Morales H. Potentially inappropriate prescribing to older adults in ambulatory care: prevalence and associated patient conditions. Eur Geriatr Med 2019;10:639-47. [PMID: 34652727 DOI: 10.1007/s41999-019-00181-5] [Reference Citation Analysis]
31 Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, Wettermark B, Ärnlöv J, Janmaat CJ, Lindholm B, Dekker FW, Coresh J, Grams ME, Carrero JJ. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology 2017;153:702-10. [PMID: 28583827 DOI: 10.1053/j.gastro.2017.05.046] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
32 Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf 2019;10:2042098618809927. [PMID: 31019676 DOI: 10.1177/2042098618809927] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
33 Peng K, Chen K, Teply BA, Yee GC, Farazi PA, Lyden ER. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients. Ann Pharmacother 2021;:10600280211033938. [PMID: 34282636 DOI: 10.1177/10600280211033938] [Reference Citation Analysis]
34 Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P, Savarino E. Latest insights into the hot question of proton pump inhibitor safety - a narrative review. Dig Liver Dis. 2020;52:842-852. [PMID: 32513631 DOI: 10.1016/j.dld.2020.04.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
35 Alhumaid S, Al Mutair A, Al Alawi Z, Zaidi ARZ, Rabaan AA, Elhazmi A, Al-Omari A. Proton pump inhibitors use and risk of developing spontaneous bacterial peritonitis in cirrhotic patients: A systematic review and meta-analysis. Gut Pathog 2021;13:17. [PMID: 33741033 DOI: 10.1186/s13099-021-00414-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Weltermann T, Schulz C, Macke L. Effect of frequently prescribed drugs on gastric cancer risk. Best Pract Res Clin Gastroenterol 2021;50-51:101741. [PMID: 33975680 DOI: 10.1016/j.bpg.2021.101741] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Conte C, Bourrel R, Despas F, Lapeyre-Mestre M. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midi-Pyrénées region. Fundam Clin Pharmacol 2019;33:327-38. [PMID: 30625254 DOI: 10.1111/fcp.12436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Uchiyama AAT, Silva PAIA, Lopes MSM, Yen CT, Ricardo ED, Mutão T, Pimenta JR, Machado LM, Shimba DS, Peixoto RD. Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. Curr Oncol 2021;28:783-99. [PMID: 33546228 DOI: 10.3390/curroncol28010076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Marabotto E, Pellegatta G, Sheijani AD, Ziola S, Zentilin P, De Marzo MG, Giannini EG, Ghisa M, Barberio B, Scarpa M, Angriman I, Fassan M, Savarino V, Savarino E. Prevention Strategies for Esophageal Cancer-An Expert Review. Cancers (Basel) 2021;13:2183. [PMID: 34062788 DOI: 10.3390/cancers13092183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Dharmarajan TS. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing. J Am Med Dir Assoc 2021;22:15-22. [PMID: 33321078 DOI: 10.1016/j.jamda.2020.09.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
41 Savarino E, Frazzoni M, Marabotto E, Zentilin P, Iovino P, Costantini M, Tolone S, Battaglia E, Cicala M, Usai-satta P, de Bortoli N, Penagini R, Savarino V. A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. Digestive and Liver Disease 2020;52:966-80. [DOI: 10.1016/j.dld.2020.04.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. J Pain Res. 2018;11:361-374. [PMID: 29491719 DOI: 10.2147/jpr.s156938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
43 Stein E, Sloan J, Sonu I, Kathpalia P, Jodorkovsky D. GERD for the nongastroenterologist: successful evaluation, management, and lifestyle-based symptom control. Ann N Y Acad Sci 2020;1482:106-12. [PMID: 32944973 DOI: 10.1111/nyas.14496] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Bang CS, Joo MK, Kim BW, Kim JS, Park CH, Ahn JY, Lee JH, Lee BE, Yang HJ, Cho YK, Park JM, Kim BJ, Jung HK; Korean College of Helicobacter and Upper Gastrointestinal Research. The Role of Acid Suppressants in the Prevention of Anticoagulant-Related Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. Gut Liver 2020;14:57-66. [PMID: 30974930 DOI: 10.5009/gnl19009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Giannini EG, Crespi M, Djahandideh A, Demarzo MG, Moscatelli A, Bodini G, Furnari M, Marabotto E, Plaz Torres MC, Zentilin P, Savarino V. Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Dig Liver Dis 2020;52:862-8. [PMID: 32505566 DOI: 10.1016/j.dld.2020.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Lazaridis LD, Rizos E, Bounou L, Theodorou-Kanakari A, Kalousios S, Mavroeidi EA, Roma M, Chatzidakis A, Vlachonicolou G, Miltiadou K, Gkolfakis P, Tziatzios G, Triantafyllou K. An educational intervention to optimize use of proton pump inhibitors in a Greek university hospital. Ann Gastroenterol 2021;34:781-7. [PMID: 34815643 DOI: 10.20524/aog.2021.0654] [Reference Citation Analysis]
47 Naunton M, Peterson GM, Deeks LS, Young H, Kosari S. We have had a gutful: The need for deprescribing proton pump inhibitors. J Clin Pharm Ther 2018;43:65-72. [PMID: 28895169 DOI: 10.1111/jcpt.12613] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
48 Goncuoglu C, Guven GS, Sener B, Demirkan K. Effect of gastric acid suppression on Clostridioides difficile-induced diarrhea and appropriateness of gastric acid suppressors in hospitalized patients: A matched case-control study. Arab J Gastroenterol 2021;22:292-6. [PMID: 34531136 DOI: 10.1016/j.ajg.2021.06.003] [Reference Citation Analysis]
49 Niu CY, Luo XC. Application of potassium competitive acid blockers in acid-related diseases. Shijie Huaren Xiaohua Zazhi 2021; 29(8): 383-388 [DOI: 10.11569/wcjd.v29.i8.383] [Reference Citation Analysis]
50 Sverdén E, Agréus L, Dunn JM, Lagergren J. Peptic ulcer disease. BMJ 2019;367:l5495. [PMID: 31578179 DOI: 10.1136/bmj.l5495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
51 Li CY, Su M, Yan YY, Zhou L, Ao LY, Fang WR, Li YM. KFP-H008 blocks gastric acid secretion through inhibiting H+-K+-ATPase. Eur J Pharmacol 2017;810:112-9. [PMID: 28629736 DOI: 10.1016/j.ejphar.2017.06.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
52 Zhu LP, Zhao JW, Chen X, Wang BM. Proton pump inhibitor usage and nonsteroidal anti-inflammatory drugs-associated small intestinal injury: How to balance risks and benefits. Shijie Huaren Xiaohua Zazhi 2018; 26(22): 1334-1339 [DOI: 10.11569/wcjd.v26.i22.1334] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Toth-Manikowski S, Grams ME. Proton Pump Inhibitors and Kidney Disease - GI Upset for the Nephrologist? Kidney Int Rep 2017;2:297-301. [PMID: 28845467 DOI: 10.1016/j.ekir.2017.01.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
54 Sattayalertyanyong O, Thitilertdecha P, Auesomwang C. The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study. Int J Clin Pharm 2020;42:174-83. [PMID: 31865594 DOI: 10.1007/s11096-019-00955-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
55 Juntunen H, Taipale H, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S, Tiihonen M. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease. Eur J Clin Pharmacol 2017;73:1149-58. [PMID: 28577224 DOI: 10.1007/s00228-017-2273-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
56 Gerber T, Zeller A. [Evidence-Based Indication for Proton Pump Inhibitors - a Group Practice Perspective]. Praxis (Bern 1994) 2021;110:193-200. [PMID: 33726514 DOI: 10.1024/1661-8157/a003623] [Reference Citation Analysis]
57 Hussain S, Siddiqui AN, Habib A, Hussain MS, Najmi AK. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis. Rheumatol Int. 2018;38:1999-2014. [PMID: 30159775 DOI: 10.1007/s00296-018-4142-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
58 Hung SC, Liao KF, Hung HC, Lin CL, Lai SW, Lee PC, Hung SR. Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study. Fam Pract 2018;35:166-71. [PMID: 29045621 DOI: 10.1093/fampra/cmx102] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
59 Malhis A, Alghamdi T, Alfandi R, Issa ZA, Alanazi H, Alfintoukh H, Baqar JB, Ali S. Appropriateness of Acid-suppressing Agents for Stress Ulcer Prophylaxis in Non-intensive Care Unit Setting in Saudi Arabia. J Pharm Bioallied Sci 2019;11:96-101. [PMID: 30906145 DOI: 10.4103/jpbs.JPBS_173_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
60 Walker MJ, Crews NR, El-Halabi M, Fayad NF. Educational Intervention Improves Proton Pump Inhibitor Stewardship in Outpatient Gastroenterology Clinics. Gastroenterology Res 2019;12:305-11. [PMID: 31803310 DOI: 10.14740/gr1238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Lanas-gimeno A, Hijos G, Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opinion on Drug Safety 2019;18:1043-53. [DOI: 10.1080/14740338.2019.1664470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
62 Meriggi F. Controversial link between proton pump inhibitors and anticancer agents: review of the literature. Tumori 2021;:3008916211025091. [PMID: 34159850 DOI: 10.1177/03008916211025091] [Reference Citation Analysis]
63 Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Syed Gaggatur N, Sange AH, Srinivas N, Sange I. Proton Pump Inhibitors: Exploring Cardiovascular Complications and Prescription Protocol. Cureus 2021;13:e16744. [PMID: 34354892 DOI: 10.7759/cureus.16744] [Reference Citation Analysis]
64 Kirmizi NI, Aydin V, Akici A. Utilization trend of gastric acid-suppressing agents in relation to analgesics. Pharmacoepidemiol Drug Saf 2021. [PMID: 34738287 DOI: 10.1002/pds.5381] [Reference Citation Analysis]
65 Segregur D, Flanagan T, Mann J, Moir A, Karlsson EM, Hoch M, Carlile D, Sayah-jeanne S, Dressman J. Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes. Journal of Pharmaceutical Sciences 2019;108:3461-77. [DOI: 10.1016/j.xphs.2019.06.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
66 van den Bunt G, Top J, Hordijk J, de Greeff SC, Mughini-Gras L, Corander J, van Pelt W, Bonten MJM, Fluit AC, Willems RJL. Intestinal carriage of ampicillin- and vancomycin-resistant Enterococcus faecium in humans, dogs and cats in the Netherlands. J Antimicrob Chemother 2018;73:607-14. [PMID: 29294027 DOI: 10.1093/jac/dkx455] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
67 Salvo EM, Ferko NC, Cash SB, Gonzalez A, Kahrilas PJ. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther 2021;54:129-43. [PMID: 34114655 DOI: 10.1111/apt.16407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
68 Oppenheimer EE, Schmit B, Sarosi GA Jr, Thomas RM. Proton Pump Inhibitor Use After Hiatal Hernia Repair: Inhibitor of Recurrent Symptoms and Potential Revisional Surgery. J Surg Res 2020;256:570-6. [PMID: 32805579 DOI: 10.1016/j.jss.2020.07.033] [Reference Citation Analysis]
69 Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Tolone S, De Bortoli N, Frazzoni M, Savarino E. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev Clin Pharmacol 2020;13:437-49. [PMID: 32253948 DOI: 10.1080/17512433.2020.1752664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Rampado S, Savarino E, Ganss A, Pozza G, Bardini R. A modified Nissen fundoplication: subjective and objective midterm results. Langenbecks Arch Surg 2018;403:279-87. [PMID: 29549453 DOI: 10.1007/s00423-018-1660-7] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Hussain S, Singh A, Habib A, Najmi AK. Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies. Clinical Epidemiology and Global Health 2019;7:46-52. [DOI: 10.1016/j.cegh.2017.12.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
72 Wang X, Liu Q, Halfdanarson ÓÖ, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer 2021. [PMID: 34253872 DOI: 10.1038/s41416-021-01480-0] [Reference Citation Analysis]
73 Liu W, Liu Y, Zhao J, Jiang H, Liu X, Ha L, Li T, Liu C, Wang F. The effectiveness of acupoint herbal patching for functional dyspepsia: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27682. [PMID: 34964729 DOI: 10.1097/MD.0000000000027682] [Reference Citation Analysis]
74 Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. The appropriate use of proton-pump inhibitors. Minerva Med 2018;109. [DOI: 10.23736/s0026-4806.18.05705-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 5.8] [Reference Citation Analysis]
75 Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017;3:CD011194. [PMID: 28271513 DOI: 10.1002/14651858.CD011194.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
76 Stasi E, Michielan A, Morreale GC, Tozzi A, Venezia L, Bortoluzzi F, Triossi O, Soncini M, Leandro G, Milazzo G, Anderloni A. Five common errors to avoid in clinical practice: the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) Choosing Wisely Campaign. Intern Emerg Med 2019;14:301-8. [PMID: 30499071 DOI: 10.1007/s11739-018-1992-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017;11:CD011194. [PMID: 29161458 DOI: 10.1002/14651858.CD011194.pub3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
78 Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [PMID: 31838548 DOI: 10.1007/s00228-019-02810-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
79 Gramont B, Bertoletti L, Roy M, Roblin X, Tardy B, Cathébras P. [Use and management of proton pump inhibitors: An observational study]. Therapie 2020;75:649-62. [PMID: 32591130 DOI: 10.1016/j.therap.2020.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Ghisa M, Barberio B, Savarino V, Marabotto E, Ribolsi M, Bodini G, Zingone F, Frazzoni M, Savarino E. The Lyon Consensus: Does It Differ From the Previous Ones? J Neurogastroenterol Motil 2020;26:311-21. [PMID: 32606254 DOI: 10.5056/jnm20046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
81 Gomila I, Barceló B, Rosell A, Avella S, Sahuquillo L, Dastis M. Cross-Reactivity of Pantoprazole with Three Commercial Cannabinoids Immunoassays in Urine. J Anal Toxicol 2017;41:760-4. [PMID: 28985315 DOI: 10.1093/jat/bkx047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
82 Boucherie Q, Rouby F, Frankel D, Roll P, Micallef J. Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database. Therapie 2018;73:385-8. [PMID: 29778306 DOI: 10.1016/j.therap.2018.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
83 Daniels B, Pearson SA, Buckley NA, Bruno C, Zoega H. Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016. Therap Adv Gastroenterol 2020;13:1756284820913743. [PMID: 32218806 DOI: 10.1177/1756284820913743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
84 Davis TME, Drinkwater J, Davis WA. Proton Pump Inhibitors, Nephropathy, and Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study. The Journal of Clinical Endocrinology & Metabolism 2017;102:2985-93. [DOI: 10.1210/jc.2017-00354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
85 Kao WY, Su CW, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology 2019;69:1151-64. [PMID: 30175498 DOI: 10.1002/hep.30247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
86 Hartlev J, Nørholt SE, Schou S, Isidor F. Pain after mandibular ramus block harvesting and lateral ridge augmentation with and without involvement of platelet-rich fibrin: a randomized controlled trial. Int J Oral Maxillofac Surg 2021;50:384-90. [PMID: 32798161 DOI: 10.1016/j.ijom.2020.07.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Biano LS, Oliveira AS, Palmeira DN, Silva LA, de Albuquerque-Junior RLC, Duarte MC, Correa CB, Grespan R, Batista JS, Camargo EA. Gastroprotective action of the ethanol extract of Leonurus sibiricus L. (Lamiaceae) in mice. J Ethnopharmacol 2021;284:114792. [PMID: 34737011 DOI: 10.1016/j.jep.2021.114792] [Reference Citation Analysis]
88 Matuz M, Benkő R, Engi Z, Schváb K, Doró P, Viola R, Szabó M, Soós G. Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Front Pharmacol 2020;11:552102. [PMID: 33013389 DOI: 10.3389/fphar.2020.552102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
89 Bell R, Lipham J, Louie B, Williams V, Luketich J, Hill M, Richards W, Dunst C, Lister D, McDowell-Jacobs L, Reardon P, Woods K, Gould J, Buckley FP, Kothari S, Khaitan L, Smith CD, Park A, Smith C, Jacobsen G, Abbas G, Katz P. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. Gastrointest Endosc. 2019;89:14-22.e1. [PMID: 30031018 DOI: 10.1016/j.gie.2018.07.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
90 Godman B, Fadare J. Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage. Curr Med Res Opin 2017;33:2085-7. [PMID: 28724310 DOI: 10.1080/03007995.2017.1358159] [Reference Citation Analysis]
91 Lin M, Zhang S, Zhang M, Shi J, Zhang C, Luo R, You J, Sun J, Zhang J, Gao F. Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23103. [PMID: 33235070 DOI: 10.1097/MD.0000000000023103] [Reference Citation Analysis]